Catalent and Toyobo team up to launch GPEx® in Japan
Published in: Outsourcing-pharma.com by Natalie Morrison
Published date: 09/21/11
Summary: Catalent has struck up a deal with Toyobo Biologics to launch its cell line engineering technology on the Japanese market. Under the agreement, Catalent will use the platform, known as GPEx®, for the manufacturing of mammalian cells while Japanese company Toyobo will provide local clinical and commercial manufacturing capabilities.